What's Happening?
A study led by researchers at the University of Pittsburgh, utilizing data from the National Institutes of Health’s 'All of Us' Research Program, has found that every individual in a diverse sample of nearly 100,000 people carried at least one genetic
variant affecting how their body processes medications. The research, published in Science Translational Medicine, also revealed that approximately a quarter of these participants had been prescribed a medication known to be impacted by a variant they possessed. Philip E. Empey, PharmD, PhD, associate professor at Pitt’s School of Pharmacy and associate director for pharmacogenomics at the Institute for Precision Medicine at Pitt and UPMC, is the senior author of the study. The team evaluated 16 genetic variants known to influence drug effectiveness or toxicity and identified over 17,000 novel variants, particularly within American and African ancestry groups, where such frequencies were previously underrepresented.
Why It's Important?
This discovery underscores the significant value of genetic testing in guiding medication prescriptions, a field known as pharmacogenomics (PGx). The findings suggest that a substantial portion of the population could benefit from personalized medicine approaches to avoid adverse drug reactions or ineffective treatments. The study highlights the potential for electronic health record (EHR) alerts to inform clinicians about genetic variants that may impact prescribed medications, allowing for dosage adjustments or alternative drug selections. This could lead to improved patient outcomes, reduced healthcare costs associated with trial-and-error prescribing, and a more efficient healthcare system. The inclusion of a diverse cohort from the 'All of Us' program is particularly important, as it addresses historical gaps in genetic research that have often skewed risk estimates and limited the applicability of findings to broader populations.
What's Next?
The researchers suggest that policy makers and health insurers will need to evaluate the benefits of widespread genetic screening for drug-impacting variants against the associated costs. Empey advocates for screening patients with a panel test for common variants, integrating these results into their medical records, similar to kidney function tests. This approach is already being applied to patients on multiple medications or those starting drugs known to be genetically impacted, such as clopidogrel. For individuals who have already undergone pharmacogenomic testing, sharing results with pharmacists and prescribers is crucial for integration into their EHRs. The ongoing research in this area aims to facilitate the responsible implementation of precision medicine in prescribing, making it a more commonplace practice as costs decrease and data availability increases.
Beyond the Headlines
The integration of pharmacogenomics into routine clinical practice represents a paradigm shift in healthcare, moving from a generalized approach to highly individualized treatment plans. This transition raises important questions about data privacy, the ethical implications of genetic information, and the potential for disparities in access to advanced genetic testing. As AI and technology continue to advance, the ability to analyze and act upon complex genetic data will become more sophisticated, further embedding precision medicine into the fabric of healthcare. However, ensuring that clinicians are adequately trained to interpret and apply this information, and that healthcare systems are equipped to handle the influx of genetic data, will be critical for successful implementation. The long-term impact could be a healthcare system that is not only more effective but also more proactive in preventing adverse drug events and optimizing therapeutic outcomes.
